Objective: Differences in cognition and brain structure have been found in youth with type 1 diabetes compared with controls, even after relatively short disease duration. To determine whether severity of clinical presentation contributes to these differences, we obtained structural magnetic resonance imaging (MRI) scans in youth ages 7-17 who were either newly diagnosed with type 1 diabetes (<3.5 months from diagnosis, n = 46) or a sibling without diabetes (n = 28).
| INTRODUCTION
Type 1 diabetes mellitus typically is diagnosed during childhood and over time can lead to complications affecting the retina, heart, kidneys, peripheral nerves, and more recently appreciated, the brain.
During childhood, the brain undergoes significant structural and functional changes including a high and rapidly changing metabolic demand, which may make the developing brain especially vulnerable to glycemic extremes.1-3 Accordingly, in youth with type 1 diabetes and varying duration of disease, studies find that early age of onset, accumulated exposure to hyperglycemia and repeated severe hypoglycemia during development are associated with lower cognitive performance and altered brain structure.2,4-14 Our group and others have found intriguing relationships between structural brain differences and previous exposure to glycemic extremes in crosssectional studies of youth with long duration type 1 diabetes. 15 Across several studies, greater chronic exposure to hyperglycemia has been associated with lower gray and white matter volume in posterior cortical regions of the brain, most commonly the precuneus/cuneus cortex and history of significant glycemic excursions have been related to hippocampal and thalamic differences. However, variability in brain outcomes remains unexplained and may relate to the difficulty in disentangling often co-occurring factors of clinical presentation severity, subsequent exposure to chronic hyperglycemia or repeated hypoglycemia that can occur during a lifetime of diabetes. 15 Some studies have observed altered cognition and brain structure in children with a relatively short duration of illness, 16,17 suggesting that factors at clinical presentation may affect brain and cognitive function later on in the disease. Prior to diagnosis, children may have prolonged exposure to marked unrecognized hyperglycemia and as many as 30% present in a state of life-threatening metabolic derangement known as diabetic ketoacidosis (DKA). [18] [19] [20] Despite the high prevalence of these complications at diagnosis in childhood, few studies have investigated their longer lasting impact on the brain. In a previous paper, we found an association between DKA and hyperglycemia at diagnosis and memory performance approximately 3 months post-diagnosis in children with type 1 diabetes. 21 Moreover, a recent study found that DKA at diagnosis was associated with differences in white matter diffusivity and volume days afterwards, most of which resolved by 6 months. Interestingly, these initial differences were associated with poorer memory and attention 6 months later. 22 However, this study did not have a control group without diabetes or an assessment of hyperglycemia at diagnosis, and our previous paper did not address underlying brain structural effects. Thus, the goal of this study was to determine whether hyperglycemia and DKA at diagnosis contribute to brain structural differences several months postdiagnosis in youth with type 1 diabetes and to determine whether these effects are discrepant from normal brain development.
| METHODS

| Subjects
Subjects between 7-17 years of age with type 1 diabetes and their eligible siblings without type 1 diabetes were recruited from the Pediatric Diabetes Clinic at Washington University in St. Louis and St. Louis Children's Hospital (SLCH). Individuals with type 1 diabetes were recruited within 3 months of diagnosis and were excluded for chronic diseases other than type 1 diabetes, history of psychiatric or neurological disorder or use of psychoactive medications or premature birth (less than 36 weeks gestation) with complications. Individuals with contraindications to magnetic resonance imaging (MRI) such as claustrophobia, orthodontic braces, or metal implants were also excluded. All procedures were approved by the Washington University School of Medicine Human Research Protection Office, and all participants and their parents or guardians signed informed consent forms.
| Clinical variables
SLCH medical records for each individual with type 1 diabetes were examined, and the following clinical variables from the time of diagnosis were collected: Tanner pubertal stage, blood glucose level (mg/dL), hemoglobin A1c (HbA1c; Alere Afinion™ AS100 Analyzer, Orlando, FL, USA), bicarbonate (HCO3 in mmol/L; ABL 837 Flex Analyzer Radiometer Gas Machine, Radiometer Medical Aps, (Copenhagen, Denmark)), blood urea nitrogen (BUN in mmol/L), sodium (Na in mEq/L), and osmolarity (osmol/L). Osmolarity was calculated using the formula (2 × Na) + (blood glucose/18) + (BUN/2.8). Study visits were scheduled to occur within 3.5 months of the inpatient diagnosis. At these visits, participants underwent an MRI scan (details below), cognitive testing21 and were asked to report any episode of severe hypoglycemia or DKA occurring between the time of diagnosis and the study date. Severe hypoglycemia was defined as in the DCCT as a low blood sugar event with neurologic dysfunction such as seizure or loss of consciousness in which the patient required the help of another person for treatment, and which improved following the administration of carbohydrate or glucagon.24 Due to the small number of participants that had both valid cognitive and neuroimaging data, analyses here include only neuroimaging outcomes. Cognitive outcomes have previously been reported. 21 
| MRI scans
All structural brain images were acquired on a Siemens 3T Tim Trio MRI scanner (Siemens Medical Solutions, Erlangen, Germany) with a 12-channel head coil at the Center for Clinical Imaging Research (CCIR) at Washington University. Blood glucose levels were measured before and after scanning and had to be between 70 and 300 mg/dL prior to starting scanning in order to proceed. The following sequences were performed: T1-weighted using magnetization-prepared rapid gradient echo to an atlas to quantify regional volumes. Left and right volumes were averaged and all were corrected for intracranial volume (ICV or volume within the skull, derived from Freesurfer).26 A priori regions of interest were hippocampal and thalamic volumes, due to findings associating these regions with hyperglycemia and DKA in previous work.27 -29 In addition, exploratory analyses were performed on a select number of other regions (n = 11: brainstem, cerebellar gray matter, cerebellar white matter, pallidum, corpus callosum, amygdala, caudate, putamen, accumbens, total cortical gray, total cortical white matter).
| Surface-based and vertex-wise cortical metrics
To determine values for cortical thickness, surface area, and volume independent of anatomical landmarks, we reconstructed and segmented individual subjects' cortical surfaces using Freesurfer (v5.3). [30] [31] [32] A triangular tessellation was applied across each subjects' cortical surface after identifying the pial surfaces and the gray/white matter border. From these maps, multiple surface-based measurements were calculated at the vertices of the triangular mesh. Cortical thickness is the distance between the white and pial surfaces, surface area is the sum of the areas of the triangles connected to a vertex, and gray matter volume is the product of cortical thickness and surface area. 
| White matter tract structural integrity
DWI images were atlas-transformed, and fractional anisotropy,33 mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated34,35 and analyzed with a voxel-wise tractbased spatial statistics (TBSS) approach36 as previously published.4
Briefly, TBSS uses the calculated fractional anisotropy (FA) images to produce a mean FA skeleton to represent the center of the white matter tracts. FA images were projected onto the mean FA skeleton and thresholded at FA = .2. TBSS was used to compare group differences across the FA skeleton. We also calculated MD, AD, and RD images, and analyzed all images using Randomise (FSL, FMRIB, Oxford, UK), a permutation-based statistical approach that corrects for multiple comparisons. 37 To ensure that motion artifacts were not responsible for any findings observed in DWI data, the number of rejected outlier data was collected from the image processing steps, and the number of bad encodes per subject was compared between groups (type 1 diabetes vs control) and type 1 diabetes subgroups (DKA+ vs DKA−).
| Data analysis
Comparisons of demographic and clinical characteristics between groups (type 1 diabetes vs control) and type 1 diabetes subgroups (DKA + vs DKA−) were performed with t-tests and chi-square tests as appropriate (significance set at P < .05). For each neuroimaging metric, three primary analyses were performed, all of which controlled for age and sex: (1) univariate analyses to compare type 1 diabetes vs control groups, (2) univariate analyses to compare DKA+ vs DKA− subgroups, and (3) hierarchical linear regression to determine if HbA1c at diagnosis was associated with the neuroimaging metric (significance set at P < .05). For the two a priori determined regions of interest (hippocampus and thalamus volumes), significance was set at P < .05. For the 11 exploratory volumes, Bonferroni correction was applied, yielding an adjusted alpha of .0045. For voxel-wise and vertex-wise whole brain analyses, the multiple comparison correction inherent in each software package was used. For any significant regions or clusters, the volume or mean value was extracted for each subject individually. These values were examined to confirm the original findings and to explore additional potential mediating variables such as time between diagnosis and study visit (disease duration), parental education, blood glucose at time of scan, and HbA1c at follow-up.
| RESULTS
| Subjects
Seventy-three individuals were scanned (type 1 diabetes n = 46, control n = 27) ( Table 1 ). Participants with type 1 diabetes were scanned between 3 weeks and 3.5 months after diagnosis. Twelve of these subjects had DKA at presentation (mild DKA n = 7, moderate DKA n = 3, and severe DKA n = 2). All patients with moderate and severe DKA were treated with insulin drips; one patient with severe DKA was admitted to the ICU and had altered mental status on arrival.
After diagnosis, all subjects with type 1 diabetes were treated with an intensive basal-bolus insulin regimen with four injections per day.
No subject experienced severe hypoglycemia or additional DKA events between diagnosis and scanning.
Five participants did not complete diffusion tensor imaging (DTI) images, and six participants did not have compatible MPRAGE scans due to a change in scanning protocol. These issues left 67 subjects with usable MPRAGE images (type 1 diabetes n = 42, control n = 25) and 68 subjects with usable DTI images (type 1 diabetes n = 44, control n = 24). One control was missing parental years of education, one participant with type 1 diabetes was missing blood glucose levels prior to scanning, and another type 1 diabetes participant was missing a follow-up HbA1c value. Groups (type 1 diabetes vs control) and subgroups (DKA+ vs DKA−) did not differ in any demographic or clinical characteristics (P > .05) ( Tables 1 and 2 ). Given the limited number of subjects with moderate or severe DKA, statistical analyses could not be performed across DKA severity categories. Finally, we repeated these last analyses after removing the three patients with <1 month duration of T1DM and found somewhat similar results despite the reduced power (thalamus, P = .058; hippocampus, P = .067).
| Exploratory regions
Groups (type 1 diabetes vs control; DKA+ vs DKA−) did not differ in volumes in any of these regions (Table 3) 
| Cortical volume, thickness, and surface area
The type 1 diabetes group had lower cortical volume in the left hemisphere at the temporal-parietal-occipital cortical junction compared with controls ( Figure 2A ) after correcting for multiple comparisons. Higher HbA1c at diagnosis correlated with lower cortical thickness in the posterior parietal lobe and with greater cortical thickness in the occipital lobe ( Figure 2C ). Of note, prior to multiple comparisons correction, the left hemisphere had a cluster of lower cortical thickness in the posterior parietal lobe similar in location and shape to the cluster on the right hemisphere, but this did not remain significant after correction for multiple comparisons. Thicknesses within these clusters were extracted for each subject and examined, confirming the relationship for the parietal cluster [F Change (1, 38) = 11.13, P = .002]. This effect was still present after additionally covarying parental education, diabetes duration, HbA1c at follow-up, DKA status, and blood glucose at the time of scan [F Change (1, 32) = 8.69, P = .006]. We repeated this last analysis after removing the three patients with <1 month duration of T1DM and found similar results (P = .016).
In order to explore how those with type 1 diabetes and with higher HbA1c compared with controls, we divided the type 1 diabetes group by the median HbA1c value (11.5) and performed a univariate analysis on the "lower" and "higher" type 1 diabetes subgroups and controls, covarying for age, sex, and parental education. 
| White matter tract structural integrity
There was no difference in number of excluded outlier measurements due to movement between type 1 diabetes and control subjects We repeated these last analyses after removing the three patients with <1 month duration of T1DM and found similar results (RD, P < .001; AD, P < .001). In addition, when the control group was added to the model, the main effect of group was still significant after covarying age, sex, and parental education [RD: F(2,61) = 14.22, P < .001; AD: F(2,61) = 16.28, P < .001] and the DKA+ group also had lower RD and AD compared the DKA− group and to the control group (P < .001), but the DKA-and control groups were not different from each other (RD: P = .17, AD: P = .09). (2) Although there was some variability in disease duration (3 weeks to 3.5 months), this variable was skewed (mean = 2.14 months) and also did not explain our findings in post-hoc analyses. for the integrity of the data and the accuracy of the data analysis.
| DISCUSSION
